Apellis announces NEJM published ‘positive’ Phase 3 EMPAVELI study data

The company states: “Apellis (APLS) Pharmaceuticals announced that The New England Journal of Medicine published positive results from the Phase 3 VALIANT study investigating EMPAVELI for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, which are severe and rare kidney diseases. The data published in NEJM highlight the positive Phase 3 VALIANT results at Week 26, which were consistent across adolescent and adult patients with C3G and primary IC-MPGN, including patients with C3G recurring after transplant.” “The positive data published in the New England Journal of Medicine underscore the unprecedented benefits of EMPAVELI across all three key markers of disease,” said Carla Nester, M.D., MSA, FASN, senior author, professor of internal medicine and pediatrics and director of pediatric nephrology, University of Iowa Stead Family Children’s Hospital. “C3G and primary IC-MPGN often lead to kidney failure, and the need for a kidney transplant or dialysis can be devastating. EMPAVELI represents a significant advance in treatment, and I’m thrilled that patients now have access to this important medicine.”